Tag
Presentation of three neuroendocrine tumor cases illustrating theranostics integration in diagnosis, treatment, and management, highlighting receptor-based imaging and personalized radionuclide therapy.
An early single-institution series suggests histotripsy may offer noninvasive local control for neuroendocrine liver metastases, with complete response after full-coverage treatment but important safety concerns, particularly acute kidney i
An international multicentre study of 1,240 patients reveals that autoimmune gastritis presentation varies by region, with distinct risk factors—including age, intestinal metaplasia, and extreme hypergastrinemia—driving the development of g
A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highl
The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting
